Stock Overview
BridgeBio Pharma Inc (BBIO)
NASDAQ · Healthcare · Biotechnology
BridgeBio Pharma Inc is a Healthcare company with a market capitalization of $13.76B.
Market Cap
$13.76B
Price/Sales
23.7
Price/Book
123.7
EV/EBITDA
-9.4
Beta
0.98
EPS (TTM)
$-3.74
Profit Margin
-124.4%
ROE
-1790.0%
52W High
$84.94
52W Low
$41.80
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Revenue
$502.08M
Gross Profit
$473.81M
Operating Income
-$569.09M
Net Income
-$729.31M
Free Cash Flow
-$447.01M
Total Debt
$1.87B
Cash & Equivalents
$570.12M
Shareholder Equity
-$2.08B
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 7, 2026 | $-0.84 | $-0.62 | -35.5% |
| Q4 2025 | February 24, 2026 | $-0.94 | $-0.72 | -31.1% |
| Q3 2025 | October 29, 2025 | $-0.72 | $-0.78 | +7.7% |
| Q2 2025 | August 5, 2025 | $-0.95 | $-0.60 | -58.3% |
| Q1 2025 | April 29, 2025 | $-0.99 | $-0.89 | -11.1% |
| Q4 2024 | February 20, 2025 | $-1.37 | $-1.09 | -26.1% |
Other Biotechnology Stocks
Frequently Asked Questions
What is BridgeBio Pharma Inc's market cap?
As of June 29, 2026, BridgeBio Pharma Inc (BBIO) has a market capitalization of $13.76B.
Does BridgeBio Pharma Inc pay a dividend?
BridgeBio Pharma Inc does not currently pay a dividend.
What sector is BBIO in?
BridgeBio Pharma Inc is in the Healthcare sector, specifically the Biotechnology industry.
What was BridgeBio Pharma Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), BridgeBio Pharma Inc reported revenue of $502.08M and net income of -$729.31M.
Ask your own questions about BBIO
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.